Last reviewed · How we verify
Methohexitone
At a glance
| Generic name | Methohexitone |
|---|---|
| Also known as | methohexital, Brevimytal (Hikma, Germany) |
| Sponsor | St Patrick's Hospital, Ireland |
| Target | Neuronal acetylcholine receptor; alpha2/beta2, Glycine receptor subunit alpha-1, GABA-A receptor alpha-1/beta-3/gamma-2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- General anesthesia
- Local anesthesia
Common side effects
Key clinical trials
- Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT (PHASE4)
- Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs (NA)
- EEG Characteristics in ECT (EARLY_PHASE1)
- Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion (PHASE4)
- Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression (PHASE4)
- Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression (PHASE4)
- Ketamine Anesthesia for Improvement of Depression in ECT (NA)
- Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methohexitone CI brief — competitive landscape report
- Methohexitone updates RSS · CI watch RSS
- St Patrick's Hospital, Ireland portfolio CI